Literature DB >> 28479021

What keeps children with cystic fibrosis awake at night?

Moya Vandeleur1, Lisa M Walter2, David S Armstrong3, Philip Robinson4, Gillian M Nixon5, Rosemary S C Horne6.   

Abstract

BACKGROUND: Sleep disturbance is common in children with cystic fibrosis (CF) however there are limited studies investigating the causes for poor sleep quality. In a cross sectional observational study we aimed to evaluate the clinical correlates of sleep disturbance in this population.
METHODS: Children with CF (7-18years) free from pulmonary exacerbation completed medical review, overnight oximetry, the OSA-18 and 14days of actigraphy recordings with a sleep diary.
RESULTS: In addition to FEV1 <80% and low baseline SpO2, CF-related diabetes, PEG feeding and co-morbid behaviour disorder were associated with lower objective sleep quantity. Paternal smoking and a family member with a mood disorder were also associated with sleep disturbance. The use of electronic devices before bedtime was associated with lower sleep quantity and quality. FEV1, nocturnal cough, age and a behaviour disorder predicted sleep duration. FEV1, nocturnal cough, SpO2 nadir and asthma predicted sleep efficiency. Conversely, sleep efficiency independently predicted FEV1.
CONCLUSIONS: Reduced sleep quality in children with CF is related to lung health and co-morbidities. However, family characteristics and poor sleep hygiene in the child were also associated with sleep disturbance. Optimal management of CF would seem to be the primary intervention to alleviate children's sleep disturbance, however our data raises additional targets for attempts to improve sleep.
Copyright © 2017 European Cystic Fibrosis Society. All rights reserved.

Entities:  

Keywords:  Actigraphy; Oximetry; Sleep; Sleep hygiene

Mesh:

Year:  2017        PMID: 28479021     DOI: 10.1016/j.jcf.2017.04.012

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  7 in total

Review 1.  Sleep disturbances and their impact in pediatric cystic fibrosis.

Authors:  Aarti Shakkottai; Louise M O'Brien; Samya Z Nasr; Ronald D Chervin
Journal:  Sleep Med Rev       Date:  2018-07-06       Impact factor: 11.609

Review 2.  Sleep disorders in cystic fibrosis: A systematic review and meta-analysis.

Authors:  Joel Reiter; Alex Gileles-Hillel; Malena Cohen-Cymberknoh; Dennis Rosen; Eitan Kerem; David Gozal; Erick Forno
Journal:  Sleep Med Rev       Date:  2020-02-19       Impact factor: 11.609

3.  Sleep-disordered breathing in cystic fibrosis.

Authors:  Aarti Shakkottai; Samya Z Nasr; Fauziya Hassan; Sanaya Irani; Louise M O'Brien; Ronald D Chervin
Journal:  Sleep Med       Date:  2020-06-05       Impact factor: 3.492

4.  Association between habitual physical activity (HPA) and sleep quality in patients with cystic fibrosis.

Authors:  Sarah Dietz-Terjung; Wolfgang Gruber; Sivagurunathan Sutharsan; Christian Taube; Margarete Olivier; Uwe Mellies; Cordula Koerner-Rettberg; Stefanie Dillenhöfer; Florian Stehling; Matthias Welsner
Journal:  Sleep Breath       Date:  2020-07-14       Impact factor: 2.816

5.  Sleep disturbances in children with cystic fibrosis, primary ciliary dyskinesia and typically developing children during COVID-19 pandemic.

Authors:  Tugba Sismanlar Eyuboglu; Ayse Tana Aslan; Tugba Ramaslı Gursoy; Pelin Asfuroglu; Azime Sebnem Soysal; Dilek Yapar; Mustafa Necmi İlhan
Journal:  J Paediatr Child Health       Date:  2021-05-18       Impact factor: 1.929

6.  The Unfavorable Alliance of Pain and Poor Sleep in Children with Life-Limiting Conditions and Severe Psychomotor Impairment.

Authors:  Larissa Alice Dreier; Julia Wager; Markus Blankenburg; Boris Zernikow
Journal:  Children (Basel)       Date:  2018-06-21

Review 7.  Recent Advances in Chronotherapy Targeting Respiratory Diseases.

Authors:  Keshav Raj Paudel; Saurav Kumar Jha; Venkata Sita Rama Raju Allam; Parteek Prasher; Piyush Kumar Gupta; Rahul Bhattacharjee; Niraj Kumar Jha; Sukriti Vishwas; Sachin K Singh; Jesus Shrestha; Mohammad Imran; Nisha Panth; Dinesh Kumar Chellappan; Majid Ebrahimi Warkiani; Philip M Hansbro; Kamal Dua
Journal:  Pharmaceutics       Date:  2021-11-25       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.